What question did this study set out to answer?

This research aims to explore the role of focal adhesion kinase in myeloid progenitor cells with JAK2-V617F mutation.

December 8, 2025Blood

Therapeutic targeting of focal adhesion kinase (FAK) modulates oncogenic and immune pathways in myeloid progenitor cells expressing oncogenic Janus kinase 2-V617F.

View Full Paper

Ask AI

Bookmark

Authors

Experiments show ruxolitinib and focal adhesion kinase inhibitors reduce apoptosis and immune evasion in myeloid progenitor cells.

This research aims to explore the role of focal adhesion kinase in myeloid progenitor cells with JAK2-V617F mutation.
Cultured murine 32D myeloid cells with JAK2 mutations and treated with ruxolitinib and FAK inhibitor.
Analyzed protein interactions and expression using co-immunoprecipitation and Western blot techniques.
Assessed apoptosis through flow cytometry and determined drug synergy with the Coefficient of Drug Interaction.
Performed transcriptomic analysis on patient samples to evaluate changes in gene expression.
Ruxolitinib reduces FAK phosphorylation, indicating its dependence on the JAK2-V617F mutation.
FAK inhibition significantly reduces cell viability in myeloid progenitor cells, particularly when combined with ruxolitinib.
Transcriptomic analysis reveals increased FAK expression in MPN patients compared to healthy donors.
Co-treatment with ruxolitinib and FAK inhibitor leads to a notable reduction in PD-L1 and TIM-3 immune checkpoint molecules, indicating disruption of immune evasion.

Nimmagadda et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Experiments show ruxolitinib and focal adhesion kinase inhibitors reduce apoptosis and immune evasion in myeloid progenitor cells.

This research aims to explore the role of focal adhesion kinase in myeloid progenitor cells with JAK2-V617F mutation.
Cultured murine 32D myeloid cells with JAK2 mutations and treated with ruxolitinib and FAK inhibitor.
Analyzed protein interactions and expression using co-immunoprecipitation and Western blot techniques.
Assessed apoptosis through flow cytometry and determined drug synergy with the Coefficient of Drug Interaction.
Performed transcriptomic analysis on patient samples to evaluate changes in gene expression.
Ruxolitinib reduces FAK phosphorylation, indicating its dependence on the JAK2-V617F mutation.
FAK inhibition significantly reduces cell viability in myeloid progenitor cells, particularly when combined with ruxolitinib.
Transcriptomic analysis reveals increased FAK expression in MPN patients compared to healthy donors.
Co-treatment with ruxolitinib and FAK inhibitor leads to a notable reduction in PD-L1 and TIM-3 immune checkpoint molecules, indicating disruption of immune evasion.

Nimmagadda et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark